BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (BTAI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BTAI · as of Sep 30, 2025
Ownership Breakdown
36
Institutional Holders
▲ 1 vs Q2
$6.05M
Total Inst. Value
▲ $4.86M vs Q2
30.88M
Shares Outstanding
freeFloat 95.37%
2.36M
13F Shares Held
▲ 1.74M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BTAI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 1.03M | 13.11% | 13.11% | $2.63B | Nov 14, 2025 | NEW |
OAKTREE CAPITAL MANAGEMENT LP pharmaceutical preparations | 241.2K | 3.08% | 3.08% | $617.44M | Nov 13, 2025 | — held |
FMR LLC pharmaceutical preparations | 198.6K | 2.53% | 2.53% | $508.42M | Nov 13, 2025 | ▲ 198.6K |
VANGUARD GROUP INC pharmaceutical preparations | 192.1K | 2.45% | 2.45% | $491.84M | Nov 7, 2025 | ▲ 173.3K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 125.2K | 1.60% | 1.60% | $320.62M | Nov 12, 2025 | ▲ 97.1K |
XTX TOPCO LTD pharmaceutical preparations | 113.4K | 1.45% | 1.45% | $290.21M | Nov 14, 2025 | ▲ 89.9K |
BLACKROCK, INC. pharmaceutical preparations | 84.3K | 1.07% | 1.07% | $215.76M | Nov 12, 2025 | ▲ 66.5K |
STATE STREET CORP pharmaceutical preparations | 52.7K | 67.22% | 67.22% | $134.96M | Nov 14, 2025 | NEW |
UBS GROUP AG pharmaceutical preparations | 43.5K | 55.52% | 55.52% | $111.47M | Nov 13, 2025 | ▲ 3.7K |
OAKTREE FUND ADVISORS, LLC pharmaceutical preparations | 42.9K | 54.72% | 54.72% | $109.86M | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
14
Increased
+669.7K shares9
New Positions
first time holders3
Decreased
−1.3K shares9
Sold Out
fully exitedNet shares change (top 50)
+668.4K
+669.7K / −1.3K
Net new holders
+11
9 new / 9 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BTAI insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
8
Buy transactions
12
Sell transactions
0.67
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Yocca Frank Chief Scientific Officer | May 20, 2026 | Sale | 6,845 | $1.08 | $7.4K | 26.2K | Form 4 ↗ |
Rodriguez Javier See Remarks | May 20, 2026 | Sale | 6,560 | $1.08 | $7.1K | 26.8K | Form 4 ↗ |
Steinhart Richard I Chief Financial Officer | May 20, 2026 | Sale | 6,845 | $1.08 | $7.4K | 26.3K | Form 4 ↗ |
Mehta Vimal CEO and President | May 20, 2026 | Sale | 19,419 | $1.09 | $21.1K | 69.6K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
BioXcel Therapeutics, Inc. (BTAI) is primarily owned by institutional investors, who hold approximately 7.6% of total shares outstanding. Company insiders own approximately 4.63%, while retail and public investors account for the remaining 87.73%.
The largest institutional shareholder of BioXcel Therapeutics, Inc. is MILLENNIUM MANAGEMENT LLC, holding approximately 1.03 million shares — equal to 13.11% of outstanding shares — as of September 30, 2025.
A total of 36 institutional investors currently hold BTAI stock, with a combined institutional value of approximately $6,053,707 as of the most recent 13F filing period.
Frequently asked questions
BTAI ownershipBioXcel Therapeutics, Inc. (BTAI) is primarily owned by institutional investors, who hold approximately 7.6% of shares. The largest shareholder is MILLENNIUM MANAGEMENT LLC with a 13.11% stake. Company insiders hold 4.63%. Data sourced from SEC Form 13F as of September 30, 2025.